Search

Andy Minn, MD, PhD, will return to Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Chair of MSK’s new Immuno-Oncology Program in August.

Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD, a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment, which is effective immediately, Dr. Cahlon will help oversee the network’s outpatient clinical programs, which span seven locations across New York and New Jersey.

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).

Learn from MSK experts about how to quit smoking if you have cancer. It starts with having honest conversations about smoking and nicotine addiction.

Memorial Sloan Kettering Cancer Center has filed an application with the New York State Department of Health to open a freestanding outpatient facility in Harrison, New York. If approved, the new 114,000-square-foot treatment facility will offer area residents the most advanced cancer care services, closer to home.

Despite the promise of eventually using artificial intelligence to detect melanoma, much more research and development are needed, MSK experts find.

Cancer DNA taken from spinal fluid could serve as a liquid biopsy that provides information on brain tumor mutations.

The $50 million donation from Mike and Maria Repole and the Nonna’s Garden Foundation will support cancer care on Long Island and significantly advance research efforts.